

**Supplementary Table 1** Clinical characteristics of the subjects

	Study 1		Study 2	
	Case proteinuria	control	Case proteinuria	control
Sex (M:F)	505:244†§	267:285‡	302 : 147§	555 : 410
Age (year)	60.1 ± 0.4§	62.4 ± 0.5	64.7 ± 0.4	64.8 ± 0.3
BMI (kg/m <sup>2</sup> )	23.7 ± 0.2	23.6 ± 0.2	23.5 ± 0.2	23.8 ± 0.1
HbA1c (%)	7.6 ± 0.2	7.6 ± 0.1	8.0 ± 0.1	8.1 ± 0.1
SBP (mmHg)	140 ± 1§	132 ± 1	141 ± 1§	134 ± 1
DBP (mmHg)	76 ± 0.5§	74 ± 0.5	77 ± 0.5	77 ± 0.4
Duration (year)	19.3 ± 0.4§	15.3 ± 0.4	Not available	Not available

	Study 3*		Study 4	
	Progression proteinuria	control	case ESRD	control
Sex (M:F)	20:12	110:58	199 : 101	149 : 69
Age (year)	60.9 ± 1.7	60.4 ± 0.7	64.4 ± 0.6	65.0 ± 0.7
BMI (kg/m <sup>2</sup> )	24.9 ± 0.5	23.9 ± 0.3	22.1 ± 0.2§	23.4 ± 0.3
HbA1c (%)	7.7 ± 0.2	7.4 ± 0.1	6.12 ± 0.07§	6.80 ± 0.07
SBP (mmHg)	138 ± 3	137 ± 1	142 ± 1§	121 ± 1
DBP (mmHg)	77 ± 2	77 ± 1	73 ± 1§	69 ± 1
Duration (year)	14.5 ± 1.6	12.8 ± 0.7	21.9 ± 0.9§	16.3 ± 0.4

Values are mean ± SE, NA: not available

\*Data at baseline are presented † information for 5 subjects are unknown ‡ information for 6 subjects are unknown

§P < 0.05 vs. control

**Supplementary Table 2** Genotype data of candidate SNPs in Japanese subjects with type 2 diabetes

SNP (risk allele*)		Nephropathy (11/12/22) †	P for HWET‡	Control (11/12/22) †	P for HWET‡
rs39059 (A* > G)	Study 1	220/325/146	0.20	125/242/106	0.59
	Study 2	137/226/126	0.10	254/465/225	0.67
	Study 3	16/10/5	0.14	50/71/43	0.09
	Study 4	84/154/51	0.17	58/115/45	0.39
rs39075 (G* > A)	Study 1	223/335/154	0.18	126/240/104	0.61
	Study 2	140/228/114	0.26	254/476/201	0.43
	Study 3	16/9/5	0.09	52/73/34	0.38
	Study 4	90/158/49	0.14	64/114/44	0.60
rs1888747 (G* > C)	Study 1	476/206/30	0.20	300/153/19	0.93
	Study 2	312/159/20	0.96	603/308/35	0.57
	Study 3	15/12/3	0.79	116/43/8	0.14
	Study 4	178/104/18	0.59	146/68/9	0.76
rs10868025 (A* > G)	Study 1	393/279/47	0.79	255/203/31	0.26
	Study 2	246/205/35	0.38	507/366/70	0.72
	Study 3	14/12/4	0.58	93/56/16	0.09
	Study 4	147/122/30	0.53	115/93/14	0.40
rs739401 (T > C*)	Study 1	308/325/72	0.31	221/202/49	0.78
	Study 2	212/224/45	0.20	431/383/115	0.04
	Study 3	15/13/2	0.71	63/75/26	0.64
	Study 4	136/134/28	0.54	99/98/24	0.97
rs451041 (G > A*)	Study 1	371/297/42	0.08	280/172/29	0.71
	Study 2	253/207/30	0.15	526/333/81	0.01
	Study 3	17/12/1	0.52	79/68/16	0.81
	Study 4	165/109/24	0.32	118/83/17	0.65
rs1041466 (A > G*)	Study 1	551/149/2	0.01	391/78/3	0.68
	Study 2§	263/58/8	0.03	593/131/10	0.37
	Study 3	28/2/0	0.85	138/28/1	0.74


	Study 4	233/58/6	0.30	173/43/5	0.25
rs1411766 (G > A*)	Study 1	553/155/5	0.10	391/79/3	0.65
	Study 2	369/109/10	0.56	756/185/12	0.86
	Study 3	24/5/0	0.61	133/33/0	0.16
	Study 4	221/66/11	0.04	172/50/2	0.43
rs6492208 (C > T*)	Study 1	224/357/129	0.52	161/221/88	0.43
	Study 2	158/238/90	0.98	301/465/182	0.92
	Study 3	10/14/5	0.98	65/74/27	0.45
	Study 4	95/140/65	0.32	81/97/46	0.09
rs7989848 (G > A*)	Study 1	267/351/88	0.10	188/223/62	0.75
	Study 2	189/224/72	0.67	358/447/132	0.69
	Study 3	13/14/3	0.78	76/71/16	0.92
	Study 4	111/138/51	0.47	99/91/33	0.12
rs9521445 (C > A*)	Study 1	288/341/92	0.57	200/215/64	0.61
	Study 2	194/222/73	0.47	373/442/128	0.87
	Study 3	15/13/3	0.94	80/68/17	0.65
	Study 4	113/135/50	0.37	101/86/32	0.06

\* Risk allele reported by Pezzolesi et al. †11; homozygous for major allele, 12; heterozygous, 22; homozygous for minor allele

‡ Hardy-Weinberg Equilibrium test, § DNA samples for 173 cases and 243 controls are not available.

Supplementary Figure 1. Pairwise linkage disequilibrium coefficients ( $r^2$ ) among 5 SNPs within Chromosome 13q locus (near IRS2) in JPT (A), or in CEU (B) from the HapMap database (HapMap: <http://www.hapmap.org/index.html>)

A



B

